This is a routine conference presentation announcement with no new data or financials. Monitor the September 23 presentation for any updates on the GX-03 atopic dermatitis program, particularly the pruritus-focused enrichment strategy and emerging patient subgroup findings, which could provide signals on trial design or regulatory path.
Price Chart
Executive Summary
Turn Therapeutics (TTRX) announced it will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. The presentation will focus on its atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy and emerging findings across patient populations. This is a routine investor conference presentation with no new financial data or clinical results disclosed.
Key Facts
- Turn Therapeutics will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET.
- CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D. will present.
- The presentation covers the atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy.
- Emerging findings across patient populations with moderate-severe baseline pruritus and lower EASI scores despite high IGA will be discussed.
- No financial results, guidance, or material clinical data were disclosed in this filing.
Financial Impact
No financial impact disclosed in this filing.
Risk Factors
- No material risks disclosed in this filing.
- Clinical-stage biotech risk: no revenue, reliance on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-098584 |
| Document: ea030503701ex99-1.htm | 0001213900-26-098584 |
| Document: 0001213900-26-098584-index-headers.html | 0001213900-26-098584 |
| Document: 0001213900-26-098584-index.html | 0001213900-26-098584 |
| Document: 0001213900-26-098584.txt | 0001213900-26-098584 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.61 (+1.34%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.61 (−12.31%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.61 (−20.70%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.61 (−22.84%) |
Aug 18, 2026 9w ago | 8-K | $9.99 | awaiting T+60 | — | $10.61 (+6.21%) |
Jul 7, 2026 15w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.61 (+9.27%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.61 (+76.25%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.61 (+67.61%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.61 (+100.57%) |
May 19, 2026 22w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.61 (+133.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers